AIM2, an IFN-inducible cytosolic DNA sensor, in the development of benign prostate hyperplasia and prostate cancer

Molecular Cancer Research

Volumn 11, Issue 10, 2013, Pages 1193-1202

  Ponomareva, Larissa ^a,b   Liu, Hongzhu ^a,b   Duan, Xin ^a,b   Dickerson, Eric ^a,b   Shen, Hui ^a,b   Panchanathan, Ravichandran ^b   Choubey, Divaker ^a,b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; PROTEIN AIM 2; UNCLASSIFIED DRUG; AIM2 PROTEIN, HUMAN; DNA; DNA BINDING PROTEIN; NUCLEAR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOSOL; HUMAN; HUMAN CELL; KERATINOCYTE; MACROPHAGE; MOLECULAR SENSOR; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; SENESCENCE; SIGNAL TRANSDUCTION; ADENOCARCINOMA; CELL TRANSFORMATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CYTOSOL; DNA; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMASOMES; INTERFERON-GAMMA; MALE; NUCLEAR PROTEINS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 84886384437     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0145     Document Type: Article

References (56)

1. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2000;14:2410-34.
2. Isaacs W, De Marzo A, Nelson WG. Focus on prostate cancer. Cancer Cell 2002;22:113-16.
3. Borowsky AD, Dingley KH, Ubick E, Turteltaub KW, Cardiff RD, Devere-White R, et al. Inflammation and atrophy precede prostatic neoplasia in a PhIP-induced rat model. Neoplasia 2006;8:708-15.
4. De Marzo AM, Nakai Y, Nelson WG. Inflammation, atrophy, and prostate carcinogenesis. Urol Oncol 2007;25:398-400.
5. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7: 256-69.
6. Sutcliffe S, Platz EA. Inflammation and prostate cancer: a focus on infections. Curr Urol Rep 2008;9:243-49.
7. Klein EA, Silverman R. Inflammation, infection, and prostate cancer. Curr Opin Urol 2008;18:315-19.
8. Drake CG. Prostate cancer as a model for tumor immunotherapy. Nat Rev Immunol 2010;10:580-93.
9. Orsted DD, Bojesen SE. The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol 2012;10:49-54.
10. Bostanci Y, Kazzazi A, Momtahen S, Laze J, Djavan B. Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol 2013;23:5-10.
11. Boehm BJ, Colopy SA, Jerde TJ, Loftus CJ, Bushman W. Acute bacterial inflammation of themouse prostate. Prostate 2012;72:307-17.
12. Birbach A, Eisenbarth D, Kozakowski N, Ladenhauf E, Schmidt-Supprian M, Schmid JA, et al. Persistent inflammation leads to proliferative neoplasia and loss of smooth muscle cells in a prostate tumor model. Neoplasia 2011;13:692-703.
13. Taniguchi T, Takaoka A. A weak signal for strong responses: interferon- alpha/beta revisited. Nat Rev Mol Cell Biol 2001;2:378-86.
14. Honda K, Yanai H, Takaoka A, Taniguchi T. Regulation of the type-I IFN induction: a current view. Int Immunol 2005;17:1367-78.
15. Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS, et al. . Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 1996;56:218-22.
16. Castro P, Giri D, Lamb D, Ittmann M. Cellular senescence in the pathogenesis of benign prostatic hyperplasia. Prostate 2003;55: 30-8.
17. Untergasser G, Koch HB, Menssen A, Hermeking H. Characterization of epithelial senescence by serial analysis of gene expression: identification of genes potentially involved in prostate cancer. Cancer Res 2002;62:6255-62.
18. Shou J, Soriano R, Hayward SW, Cunha GR, Williams PM, Gao WQ, et al. Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Proc Natl Acad Sci U S A 2002;99:2830-5.
19. Fridman AL, Tainsky MA. Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. Oncogene 2008;27:5975-87.
20. Duan X, Ponomareva L, Veeranki S, Panchanathan R, Dickerson E, Choubey D, et al. Differential roles for the interferon-inducible IFI16 and AIM2 innate immune sensors for cytosolic DNA in cellular senescence of human fibroblasts. Mol Cancer Res 2011;9:589-602.
21. Xin H, Curry J, Johnstone RW, Nickoloff BJ, Choubey D. Role of IFI 16, a member of the interferon-inducible p200-protein family, in prostate epithelial cellular senescence. Oncogene 2003;22:4831-40.
22. Xin H, Pereira-Smith OM, Choubey D. Role of IFI 16 in cellular senescence of human fibroblasts. Oncogene 2004;23:6209-17.
23. Coppé JP, Desprez PY, Krtolica A, Campisi J. The senescenceassociated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 2010;5:99-118.
24. Salminen A, Kauppinen A, Kaarniranta K. Emerging role of NF-kB signaling in the induction of senescence-associated secretory phenotype (SASP). Cell Signal 2012;24:835-45.
25. Mammone T, Gan D, Foyouzi-Youssefi R. Apoptotic cell death increases with senescence in normal human dermal fibroblast cultures. Cell Biol Int 2006;30:903-9.
26. Lehmann BD, Paine MS, Brooks AM, McCubrey JA, Renegar RH, Wang R, et al. Senescence-associated exosome release from human prostate cancer cells. Cancer Res 2008;68:7864-71.
27. Petrilli V, Papin S, Tschopp J. The inflammasome. Curr Biol 2005;15: R581.
28. Shaw PJ, McDermott MF, Kanneganti TD. Inflammasomes and autoimmunity. Trends Mol Med 2011;17:57-64.
29. Lamkanfi M, Dixit VM. Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol 2012;28:137-61.
30. Schattgen SA, Fitzgerald KA. The PYHIN protein family as mediators of host defenses. Immunol Rev 2011;243:109-18.
31. Choubey D, Duan X, Dickerson E, Ponomareva L, Panchanathan R, Shen H, et al. Interferon-inducible p200-family proteins as novel sensors of cytoplasmic DNA: role in inflammation and autoimmunity. J Interferon Cytokine Res 2010;30:371-80.
32. Schroder K, Tschopp J. The inflammasomes. Cell 2010;140:821-32.
33. Abdul-Sater AA, Koo E, Hacker G, Ojcius DM. Inflammasome-dependent caspase-1 activation in cervical epithelial cells stimulates growth of the intracellular pathogen Chlamydia trachomatis. J Biol Chem 2009;284:26789-96.
34. Dombrowski Y, Peric M, Koglin S, Kammerbauer C, Goss C, Anz D, et al. Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions. Sci Transl Med 2011;3:82ra38.
35. Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009;458: 514-18.
36. Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009;458:509-13.
37. Burckstummer T, Baumann C, Bluml S, Dixit E, Durnberger G, Jahn H, et al. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol 2009;10:266-72.
38. Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, Narayan P, et al. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim 1995;31:14-24.
39. Alimirah F, Chen J, Xin H, Choubey D. Androgen receptor autoregulates its expression by a negative feedback loop through upregulation of IFI16 protein. FEBS Lett 2006;580:1659-64.
40. Choubey D. DNA-responsive inflammasomes and their regulators in autoimmunity. Clin Immunol 2012;142:223-31.
41. Cowburn AS, White JF, Deighton J, Walmsley SR, Chilvers ER. z-VADfmk augmentation of TNF alpha-stimulated neutrophil apoptosis is compound specific and does not involve the generation of reactive oxygen species. Blood 2005;105:2970-72.
42. Choi J, Shendrik I, Peacocke M, Peehl D, Buttyan R, Ikeguchi EF, et al. Expression of senescence-associated beta-galactosidase in enlarged prostates from men with benign prostatic hyperplasia. Urology 2000; 56:160-66.
43. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 1997;18:1215-23.
44. Veeranki S, Duan X, Panchanathan R, Liu H, Choubey D. IFI16 protein mediates the anti-inflammatory actions of the type-I interferons through suppression of activation of caspase-1 by inflammasomes. PLoS ONE 2011;6:e27040.
45. Veeranki S, Choubey D. Interferon-inducible p200-family protein IFI16, an innate immune sensor for cytosolic and nuclear double-stranded DNA: regulation of subcellular localization. Mol Immunol 2012;49: 567-71.
46. Woerner SM, Kloor M, Schwitalle Y, Youmans H, Doeberitz MK, Gebert J, et al. The putative tumor suppressor AIM2 is frequently affected by different genetic alterations in microsatellite unstable colon cancers. Genes Chromosomes Cancer 2007;46:1080-89
47. Hasegawa S, Furukawa Y, Li M, Satoh S, Kato T, Watanabe T, et al. Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. Cancer Res 2002;62:7012-17.
48. Pedersen KS, Bamlet WR, Oberg AL, de Andrade M, Matsumoto ME, Tang H, et al. Leukocyte DNA methylation signature differentiates pancreatic cancer patients from healthy controls. PLoS ONE 2011;6:e18223.
49. DeYoung KL, Ray ME, Su YA, Anzick SL, Johnstone RW, Trapani JA, et al. Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma. Oncogene 1997;15:453-57.
50. Chen IF, Ou-Yang F, Hung JY, Liu JC, Wang H, Wang SC, et al. AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model. Mol Cancer Ther 2006; 5:1-7
51. Patsos G, Germann A, Gebert J, Dihlmann S. Restoration of absent in melanoma 2 (AIM2) induces G2/M cell cycle arrest and promotes invasion of colorectal cancer cells. Int J Cancer 2010;126: 1838-49.
52. Cresswell KS, Clarke CJ, Jackson JT, Darcy PK, Trapani JA, Johnstone RW, et al. Biochemical and growth regulatory activities of the HIN-200 family member and putative tumor suppressor protein, AIM2. Biochem Biophys Res Commun 2005;326:417-24.
53. Guo Y, Kyprianou N. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res 1999;59:1366-71.
54. Winter RN, Kramer A, Borkowski A, Kyprianou N. Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res 2001;61:1227-32.
55. Das PM, Ramachandran K, Vanwert J, Ferdinand L, Gopisetty G, Reis IM, et al. Methylation mediated silencing of TMS1/ASC gene in prostate cancer. Mol Cancer 2006;5:28.
56. Ricote M, García-Tuñón I, Bethencourt FR, Fraile B, Paniagua R, Royuela M, et al. Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer 2004;100: 1388-96.